To sign up to the Graham Hancock newsletter mailing list, please click here.
The world's first clinical trial designed to explore using a hallucinogen from magic mushrooms to treat people with depression has stalled because of British and European rules on the use of illegal drugs in research.
David Nutt, president of the British Neuroscience Association and professor of neuropsychopharmacology at Imperial College London, said he had been granted an ethical green light and funding for the trial, but regulations were blocking it.
Back to Previous...
Go to News Desk...
Enjoy the newsdesk? Please tell others about it:Tweet
Dedicated Servers and Cloud Servers by Gigenet. Invert Colour Scheme / Default